Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab
confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.